A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Completed
Genentech, Inc.
Phase 1
2012-08-13
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of
atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with
vemurafenib or vemurafenib plus cobimetinib in participants with BRAFV600-mutation positive
metastatic melanoma. Enrolled participants may continue treatment until they are no longer
experiencing clinical benefit as assessed by the investigator and in alignment with the
protocol.
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Active, not recruiting
Bristol-Myers Squibb
Phase 1/Phase 2
2013-10-24
To investigate the safety and efficacy of nivolumab as a single agent or in combination with
ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC),
pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and
ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also
investigated in PC.
An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread
Active, not recruiting
Bristol-Myers Squibb
Phase 2
2014-03-12
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination
with other anti-cancer drugs, will result in meaningful tumor size reduction, in patients
with colon cancer that has come back or has spread, and who have a specific biomarker in
their tumors.
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Active, not recruiting
Genentech, Inc.
Phase 2
2014-04-14
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of
six treatment regimens in participants with advanced solid tumors for whom therapies that
will convey clinical benefit are not available and/or are not suitable options per the
treating physician's judgment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
